With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
July 10, 2017. Will oncology be the next casualty of Brexit? This month’s ASCO op ed explores the cancer care fall-out of the UK’s departure from the EU. Drug approval processes are often fast-tracked via an EU regulatory body which will suffer a large void without the continued strong research presence of the UK. In fact, several clinical trials are conducted through single EU-registration processes. Same goes for pharmaceutical companies, who privately fund a significant portion of drug advances. For better or worse, Brexit brings big changes in clinical trial trajectories in Europe. One thing’s for sure: Like it’s English-speaking counterpart across the pond, the UK will have to work hard to keep cancer care a priority amidst an uncertain healthcare climate.